Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
This page provides a historical news feed for NanoVibronix, Inc. under the ticker NAOV, which later changed its corporate name to ENvue Medical, Inc. and its Nasdaq ticker to FEED. The archived coverage reflects the company’s evolution as a medical technology business focused on non-invasive therapeutic systems and minimally invasive navigation platforms for enteral care and related clinical applications.
News items associated with NAOV include announcements about the company’s acoustic-based therapeutic technologies, such as PainShield and UroShield, which use proprietary low-intensity surface acoustic wave technology and are intended to treat pain, reduce bacterial colonization, and disrupt biofilms in home or care settings. Releases also describe developments around the UroShield Kit, including its addition to the UK National Health Service Drug Tariff Part IX and the resulting prescription reimbursement pathway across the UK.
Another major theme in the NAOV news history is the integration and expansion of the ENvue Navigation Platform, a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. Company communications highlight FDA 510(k) clearance for adult use, real-time bedside visualization of tube movement, and plans to build a broader enteral-feeding ecosystem around this platform. Additional stories cover training initiatives, such as the Oscar training aid for naso-enteral feeding procedures, and intellectual property developments related to navigation technology.
Investors and observers can use this NAOV news archive to trace key milestones such as the strategic shift toward enteral navigation, financing transactions disclosed in press releases, and the formal rebranding to ENvue Medical, Inc. For the most recent developments after the name and ticker change, subsequent news is released under the FEED symbol.
ENvue Medical (NASDAQ: FEED) signed a nationwide distribution agreement with U-Deliver to supply its recently launched over-the-counter reusable ENFit Syringe line through non-acute channels. The syringes are available OTC via U-Deliver website, Amazon storefront, and wholesale in 2.5, 5, 10 and 60 mL sizes.
The ENFit syringes meet ISO 80369-3 standards and are designed for reuse up to seven days or 20 uses, aimed at improving enteral care access in home and long-term care settings.
ENvue Medical (NASDAQ: FEED; NASDAQ: NAOV) announced on January 21, 2026 the appointment of Marc Waldman as Vice President, Commercial to lead U.S. commercialization. Waldman brings 35+ years of medical device commercial leadership, GPO and IDN experience, and sector expertise in patient safety, enteral feeding and neonatal nutrition. He previously grew a neonatal enteral portfolio from $39M to $70M in 3.5 years and will focus on expanding ENvue’s current presence in 38 hospitals and accelerating revenue across the company’s enteral platform.
ENvue Medical (NASDAQ: FEED) announced on January 14, 2026 the launch of over-the-counter ENFit syringes for enteral feeding and medication delivery, available without a prescription. The syringes will be sold in institutional and consumer-friendly packaging and are anticipated to appear at certain online retailers including Amazon and durable medical equipment suppliers. Offered in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, the devices comply with ISO 80369-3 and are designed for reuse for up to seven days or 20 uses, aiming to support continuity of care across clinical and home settings.
ENvue Medical (NASDAQ: FEED) launched a development and integration program to evaluate its clinically validated NanoVibronix vibration technology for reducing pain and discomfort from indwelling nasogastric (NG) tubes.
The program builds on previously published, peer‑reviewed research showing surface acoustic wave micro‑vibration can reduce friction at the tube–tissue interface. The effort is exploratory and focused on technical feasibility, clinical pathway assessment, and regulatory and quality considerations, and does not represent a commercial product launch or regulatory clearance.
ENvue Medical (NASDAQ: FEED) will ring the Nasdaq Opening Bell at Nasdaq MarketSite in Times Square on Wednesday, January 14, 2026. The ceremony, led by Doron Besser, MD, CEO, will include company leadership, directors, employees, and key stakeholders. The event is scheduled for 8:30 A.M. – 9:45 A.M. ET at 151 West 43rd Street and will be available via live webcast.
This public ceremonial event highlights the company’s focus on non-invasive enteral access and non-opioid pain management technologies and offers a visibility opportunity for investors and stakeholders to observe leadership remarks and company representation.
ENvue Medical (NASDAQ:NAOV) announced that the UroShield Kit was added to the UK NHS Drug Tariff Part IX on Dec 18, 2025, establishing a nationwide prescription reimbursement pathway.
The company also secured an initial purchase order from Peak Medical, a UK distributor, providing early commercial demand signal and near-term revenue visibility heading into 2026. The UroShield Actuator was previously included in the Drug Tariff in 2023, and UroShield is intended to reduce catheter-associated urinary tract infections by applying low-frequency ultrasonic energy to catheters.
ENvue Medical (NASDAQ: NAOV) announced that the UroShield® Kit was added to the UK NHS Drug Tariff Part IX on December 18, 2025, enabling nationwide prescription reimbursement across community and hospital settings.
ENvue also secured an initial purchase order from Peak Medical, its exclusive UK distributor, signaling early commercial demand and providing near-term revenue visibility heading into 2026. The UroShield system complements the previously listed UroShield Actuator (added to Drug Tariff Part IX in 2023) and targets reduction of catheter-associated urinary tract infections (CAUTIs) in long-term catheterized populations.
NanoVibronix (NASDAQ: NAOV) will change its corporate name to ENvue Medical and begin trading under the new ticker FEED at the open of market on December 12, 2025.
The rebrand aligns the company with its primary focus on the ENvue feeding-tube placement system and a strategy to scale hospital utilization, expand commercial reach, and build an enteral-feeding ecosystem. No action is required from current stockholders and the company’s common-stock CUSIP remains unchanged.
NanoVibronix (NASDAQ: NAOV) announced a strategic refocus around the ENvue feeding-tube placement system, which the company merged into NanoVibronix in early 2025 and says is 510(k) FDA-cleared and commercially available.
The company plans to rebrand as ENvue Medical with a new NASDAQ ticker, pursue hospital scaling and R&D (pediatric, imaging-overlay, vascular access, robotic guidance), and is exploring strategic alternatives for legacy NanoVibronix technologies. NanoVibronix reports a commercial base of 38 hospitals and cites a U.S. enteral-feeding market projected at ~$1.8 billion by 2030. The Board and leadership additions will be announced after the December 4, 2025 annual meeting.
NanoVibronix (NASDAQ: NAOV) has launched Oscar, an advanced training aid through its ENvue Medical division. The platform is designed to help clinicians and educators practice naso-enteral feeding procedures in a standardized, repeatable way.
Oscar complements the company's FDA-cleared ENvue System by providing a safe training environment for healthcare professionals before working with patients. Unlike ENvue, Oscar is not classified as a medical device and will be available independently to teaching hospitals, nursing schools, and training facilities.
The company expects broader availability beginning in 2026, with Oscar contributing to revenue through training programs while accelerating ENvue adoption. This dual-purpose strategy aims to expand growth opportunities and support broader distribution channels.
FAQ
What is the current stock price of Nanovibronix (NAOV)?
What is the market cap of Nanovibronix (NAOV)?
